Hints and tips:
...Some of FGS’s biggest clients include EY, UnitedHealth, Bayer and SoftBank....
...Bayer: Shares in the German chemicals and pharma company gained 2 per cent after reports it may spin off its CropScience unit....
...China founder Neil Shen took Singapore residency (FT) Vodafone in talks to sell Italian business to Swisscom (FT) Uber’s Dara Khosrowshahi defends buyback policy (FT) Shein’s London IPO flirtation (FT) Bayer...
...In Bayer’s case, its CropScience division, which provides seeds and weedkillers to farmers, feared in 2016 that it could be marginalised as a massive consolidation wave swept through the sector....
...“We were perplexed by their publicly announced ESG investment in Bayer,” said Michael Weinberg, adjunct professor of business at Columbia Business School, who knows the hedge fund well....
...LPs finding themselves overcommitted to the asset class on the tail-end of the decade-long boom are also selling stakes in large buyout funds in the secondaries market, selling at up to 20 per cent discounts...
...Bayer’s shares have risen 10 per cent since Ubben’s stake was disclosed, compared with a 2 per cent rise in Germany’s Dax stock index. Bayer has declined to comment on Ubben’s investment....
...Bloomberg LP is wedded to the idea of one price, one product — the ultimate bundle....
...While we’re on the topic of M&A deals gone sour, ears will be burning over at Bayer....
...watchdogs, Makan Delrahim from the US justice department and EU competition boss Margrethe Vestager, are set to meet in Brussels: A couple of big deals under their jurisdictions are still pending, including Bayer-Monsanto...
...As well as those deals, CVS’s $68bn takeover of Aetna, Bayer’s $57bn purchase of Monsanto and United Technologies $30bn bid for Rockwell Collins all need to be funded in the US debt market this year....
...By acquiring Bayer’s diabetes care business in early 2016 and combining it with the Panasonic division, the new owner was able to double revenues....
...However ebitda at its agricultural arm CropScience, which sells products such as insecticides and herbicides as well as seeds, fell 9.5 per cent year-on-year to €334m....
...Monsanto has a market value of $40.4bn while Bayer has a market value of nearly €84bn....
...In Bayer’s case, the shift to life sciences started as long ago as 2001, when the group paid €7.25bn for Aventis CropScience in what was then its largest acquisition....
...Meanwhile, with expectations high of an imminent realignment of the global agrochemicals sector, other interested parties such as BASF, Bayer, Syngenta and Monsanto can be expected to take a close look at...
...He said that Bayer had been its flagship partner for two decades....
...Julian Little of Bayer CropScience disagreed....
...Bayer and Novartis both expressed interest in buying Zoetis before it was carved out of Pfizer, but the rules governing spin-offs made it difficult for them to acquire it during the two years after it became...
...The German pharmaceuticals group Bayer has expressed interest in acquiring additional life sciences businesses and has been tipped as a potential bidder....
...Bayer shares do not look terribly expensive next to peers....
...(Financial Times) “Bayer, Europe’s biggest pharmaceutical and chemicals conglomorate, is exploring a sale of its $10 billion plastics unit to focus on growing the health business, according to people with...
...Companies like Bayer Cropsciences, Kaveri Seeds and Pesticides India are well placed to benefit from this trend. Saurabh Mukherjea is CEO of institutional equities, Ambit Capital....
...CropScience Syed Manzur Elahi, Chairman, Apex Adelchi Footwear Eduardo Eurnekian, CEO, Corporación América Douglas Flint, Group Chairman, HSBC Holdings Antonio Estrany y Gendre, President, Axion Energy...
International Edition